All lobbying filings

BIOMARIN PHARMACEUTICAL INC.

Lobbying for BIOMARIN PHARMACEUTICAL INC.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · California · House · Senate · $270,000.00 expenses · posted Jul 21, 2025

Official filing document

Bills named in this filing 7

HR 1262
Mikaela Naylon Give Kids a Chance Act
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
HR 946
ORPHAN Cures Act
HR 1509
Accelerating Kids’ Access to Care Act of 2025
S 752
Accelerating Kids’ Access to Care Act
S 1637
MVP Act
S 1862
ORPHAN Cures Act

Lobbying activity 4

Health Issues

HR 1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S 932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING INFLATION REDUCTION ACT AND ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND NEWBORN SCREENING

Medicare/Medicaid

H.R. 1: ONE BIG BEAUTIFUL BILL ACT; PROVISIONS RELATED TO TITLE VII, SUBTITLE B H.R. 946: ORPHAN Cures Act; ALL PROVISIONS H.R. 1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S. 752: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S. 1637: MEDICAID VBPS FOR PATIENTS (MVP) Act; ALL PROVISIONS S. 1862: ORPHAN Cures Act; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING FOREIGN DRUG REFERENCE PRICING

Tariff (miscellaneous tariff bills)

GENERAL DISCUSSIONS REGARDING TARIFFS ON PHARMACEUTICALS

Taxation/Internal Revenue Code

GENERAL DISCUSSIONS REGARDING ORPHAN DRUG TAX CREDIT

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.